Impact of Fecal Calprotectin Measurement on Decision-making in Children with Inflammatory Bowel Disease

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2017 Feb 10

PMID 28180127

Citations 8

Authors

Wael El-Matary

Esmail Abej

Vini Deora

Harminder Singh

Charles N Bernstein

Affiliations

Soon will be listed here.

Abstract

Background: The use of fecal calprotectin (FCal) as a marker of intestinal inflammation, in the management of inflammatory bowel disease (IBD) is increasing. The aim of this study was to examine the impact of FCal measurements on decision-making and clinical care of children with IBD.

Materials And Methods: In a retrospective cohort study, FCal, clinical activity indices, and blood markers were measured in children with established diagnoses of IBD. Pearson correlation coefficient analysis was performed to examine association between FCal and other markers. Decisions based on FCal measurements were prospectively documented and participants were evaluated 3-6 months later.

Results: A total of 115 fecal samples were collected from 77 children with IBD [median age 14, interquartile range (IQR) 11-15.6 years, 42 females, 37 with Crohn's disease]. FCal positively correlated with clinical activity indices ( = 0.481, < 0.05) and erythrocyte sedimentation rate ( = 0.40, < 0.05) and negatively correlated with hemoglobin ( = -0.40, < 0.05). Sixty four out of 74 (86%) positive FCal measurements (≥250 μg/g of stools) resulted in treatment escalation with subsequent significant clinical improvement while in the FCal negative group, 34 out of 41 (83%) measurements resulted in no change in treatment and were associated with remission on follow-up.

Conclusion: Based on high FCal, the majority of children had treatment escalation that resulted in clinical improvement. FCal measurements were useful and reliable in decision-making and clinical care of children with IBD.

Citing Articles

Assessing the correlation between fecal calprotectin, blood markers and disease activity in pediatric inflammatory bowel disease.

Plume J, De A, Mutalib M Ann Gastroenterol. 2024; 37(4):436-441.

PMID: 38974077 PMC: 11226738. DOI: 10.20524/aog.2024.0892.

Treatment escalation and de-escalation decisions in Crohn's disease: Delphi consensus recommendations from Japan, 2021.

Nakase H, Esaki M, Hirai F, Kobayashi T, Matsuoka K, Matsuura M J Gastroenterol. 2023; 58(4):313-345.

PMID: 36773075 PMC: 10050046. DOI: 10.1007/s00535-023-01958-z.

Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease.

Kumric M, Zivkovic P, Kurir T, Vrdoljak J, Vilovic M, Martinovic D Diagnostics (Basel). 2022; 12(1).

PMID: 35054212 PMC: 8774757. DOI: 10.3390/diagnostics12010045.

Fecal Lactoferrin Predicts Primary Nonresponse to Biologic Agents in Inflammatory Bowel Disease.

Sorrentino D, Nguyen V, Love K Dig Dis. 2021; 39(6):626-633.

PMID: 33631768 PMC: 8686729. DOI: 10.1159/000515432.

Timely Monitoring of Inflammation by Fecal Lactoferrin Rapidly Predicts Therapeutic Response in Inflammatory Bowel Disease.

Sorrentino D, Gray J Inflamm Bowel Dis. 2021; 27(8):1237-1247.

PMID: 33501943 PMC: 8314109. DOI: 10.1093/ibd/izaa348.

References

El-Matary W, Dupuis K, Sokoro A . Anti-Saccharomyces cerevisiae antibody titres correlate well with disease activity in children with Crohn's disease. Acta Paediatr. 2015; 104(8):827-30. DOI: 10.1111/apa.13026. View

Bousvaros A, Sylvester F, Kugathasan S, Szigethy E, Fiocchi C, Colletti R . Challenges in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12(9):885-913. DOI: 10.1097/01.mib.0000228358.25364.8b. View

. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria. J Pediatr Gastroenterol Nutr. 2005; 41(1):1-7. DOI: 10.1097/01.mpg.0000163736.30261.82. View

Schoepfer A, Beglinger C, Straumann A, Safroneeva E, Romero Y, Armstrong D . Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013; 19(2):332-41. DOI: 10.1097/MIB.0b013e3182810066. View

Griffiths A, Otley A, Hyams J, Quiros A, Grand R, Bousvaros A . A review of activity indices and end points for clinical trials in children with Crohn's disease. Inflamm Bowel Dis. 2005; 11(2):185-96. DOI: 10.1097/00054725-200502000-00013. View

Sipponen T, Savilahti E, Kolho K, Nuutinen H, Turunen U, Farkkila M . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2007; 14(1):40-6. DOI: 10.1002/ibd.20312. View

Foell D, Wittkowski H, Roth J . Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut. 2009; 58(6):859-68. DOI: 10.1136/gut.2008.170019. View

Schoepfer A, Beglinger C, Straumann A, Trummler M, Vavricka S, Bruegger L . Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2009; 105(1):162-9. DOI: 10.1038/ajg.2009.545. View

Osterman M, Aberra F, Cross R, Liakos S, McCabe R, Shafran I . Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2014; 12(11):1887-93.e3. PMC: 4214893. DOI: 10.1016/j.cgh.2014.03.035. View

10.

Bunn S, Bisset W, Main M, Golden B . Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001; 32(2):171-7. DOI: 10.1097/00005176-200102000-00015. View

11.

Abej E, El-Matary W, Singh H, Bernstein C . The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease. Can J Gastroenterol Hepatol. 2016; 2016:2483261. PMC: 5059522. DOI: 10.1155/2016/2483261. View

12.

Judd T, Day A, Lemberg D, Turner D, Leach S . Update of fecal markers of inflammation in inflammatory bowel disease. J Gastroenterol Hepatol. 2011; 26(10):1493-9. DOI: 10.1111/j.1440-1746.2011.06846.x. View

13.

De Vos M, Dewit O, DHaens G, Baert F, Fontaine F, Vermeire S . Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. J Crohns Colitis. 2012; 6(5):557-62. DOI: 10.1016/j.crohns.2011.11.002. View

14.

Guardiola J, Lobaton T, Rodriguez-Alonso L, Ruiz-Cerulla A, Arajol C, Loayza C . Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol. 2014; 12(11):1865-70. DOI: 10.1016/j.cgh.2014.06.020. View

15.

van Rheenen P . Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control. Inflamm Bowel Dis. 2012; 18(11):2018-25. DOI: 10.1002/ibd.22896. View

16.

Hyams J, Ferry G, Mandel F, GRYBOSKI J, Kibort P, Kirschner B . Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991; 12(4):439-47. View

17.

Turner D, Otley A, Mack D, Hyams J, de Bruijne J, Uusoue K . Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007; 133(2):423-32. DOI: 10.1053/j.gastro.2007.05.029. View

18.

Lasson A, Ohman L, Stotzer P, Isaksson S, Uberbacher O, Ung K . Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study. United European Gastroenterol J. 2015; 3(1):72-9. PMC: 4315686. DOI: 10.1177/2050640614560785. View

19.

Canani R, Terrin G, Rapacciuolo L, Miele E, Siani M, Puzone C . Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008; 40(7):547-53. DOI: 10.1016/j.dld.2008.01.017. View

20.

Costa F, Mumolo M, Ceccarelli L, Bellini M, Romano M, Sterpi C . Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005; 54(3):364-8. PMC: 1774401. DOI: 10.1136/gut.2004.043406. View